Legal & General Group Plc grew its holdings in Emergent Biosolutions Inc (NYSE:EBS) by 4.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,378 shares of the biopharmaceutical company’s stock after acquiring an additional 3,045 shares during the quarter. Legal & General Group Plc owned 0.17% of Emergent Biosolutions worth $2,845,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Aperio Group LLC lifted its holdings in shares of Emergent Biosolutions by 5.3% during the second quarter. Aperio Group LLC now owns 11,644 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 589 shares during the period. Great West Life Assurance Co. Can lifted its holdings in shares of Emergent Biosolutions by 6.8% during the second quarter. Great West Life Assurance Co. Can now owns 50,912 shares of the biopharmaceutical company’s stock worth $1,725,000 after purchasing an additional 3,230 shares during the period. Sei Investments Co. lifted its holdings in shares of Emergent Biosolutions by 97,546.2% during the second quarter. Sei Investments Co. now owns 38,082 shares of the biopharmaceutical company’s stock worth $1,291,000 after purchasing an additional 38,043 shares during the period. Arizona State Retirement System lifted its holdings in shares of Emergent Biosolutions by 0.6% during the second quarter. Arizona State Retirement System now owns 18,160 shares of the biopharmaceutical company’s stock worth $616,000 after purchasing an additional 100 shares during the period. Finally, First Trust Advisors LP lifted its holdings in shares of Emergent Biosolutions by 169.2% during the second quarter. First Trust Advisors LP now owns 53,149 shares of the biopharmaceutical company’s stock worth $1,802,000 after purchasing an additional 33,403 shares during the period. 88.44% of the stock is owned by institutional investors and hedge funds.
In other news, Director George A. Joulwan sold 14,251 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $41.24, for a total value of $587,711.24. Following the transaction, the director now owns 34,323 shares of the company’s stock, valued at approximately $1,415,480.52. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Daniel Abdun-Nabi sold 31,508 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.77, for a total value of $1,347,597.16. Following the transaction, the chief executive officer now directly owns 215,642 shares in the company, valued at approximately $9,223,008.34. The disclosure for this sale can be found here. Insiders have sold 206,329 shares of company stock valued at $8,892,362 over the last quarter. 16.50% of the stock is owned by company insiders.
Shares of Emergent Biosolutions Inc (NYSE:EBS) opened at $46.80 on Thursday. The company has a market capitalization of $1,930.00, a P/E ratio of 29.25, a PEG ratio of 0.94 and a beta of 1.29. Emergent Biosolutions Inc has a 12-month low of $27.94 and a 12-month high of $49.25. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. During the same period in the previous year, the business earned $0.56 earnings per share. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. sell-side analysts anticipate that Emergent Biosolutions Inc will post 1.58 EPS for the current fiscal year.
A number of equities research analysts recently commented on the company. Zacks Investment Research raised Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $53.00 target price for the company in a report on Tuesday, January 2nd. Wells Fargo & Co reiterated an “outperform” rating and set a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://ledgergazette.com/2018/01/11/emergent-biosolutions-inc-ebs-shares-bought-by-legal-general-group-plc.html.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.